Tag:

Intermune

Latest Headlines

Latest Headlines

InterMune and Boehringer win tandem FDA nods for 'breakthrough' lung drugs

InterMune and Boehringer Ingelheim have spent the last year or so jockeying for the spotlight with in-development treatments for a rare lung disease, hoping to take pole position upon reaching the market. Now, as the FDA has decided to approve both drugs at once, the two companies will set off from equal starting points in the race for dominance.

Roche CEO Schwan took a hands-on approach negotiating $8.3B InterMune buyout

The flurry of meetings and phone calls between Schwan and Welch are spelled out in an SEC document InterMune filed late last week.

No deal: Report asserts that Roche has dropped any plans for Chugai buyout

The news that Roche struck a deal to buy InterMune for $8.3 billion reportedly came at the expense of Chugai's investors.

Roche is buying (again): extends biotech shopping spree with $8.3B InterMune buyout

Roche has won the behind-the-scenes auction for InterMune and its late-stage drug for idiopathic pulmonary fibrosis, announcing Sunday that it is buying up the U.S. biotech for $8.3 billion.

InterMune buyout rumors resurface, with Roche, Sanofi on the short list

InterMune's promising treatment for a rare lung disease has put it in Big Pharma's crosshairs, according to a report, news that sent the biotech's shares soaring as much as 20% on Wednesday.

InterMune bags a 'breakthrough' nod of its own in a race with Boehringer

InterMune secured the FDA's breakthrough therapy designation for an in-development treatment for a rare lung disease, evening the regulatory score with rival Boehringer Ingelheim as the two angle for position on the U.S. market.

Boehringer's lung disease drug hits the EU fast track in a race with InterMune

The European Medicines Agency has agreed to an accelerated review of Boehringer Ingelheim's much-watched lung disease therapy, likely shortening its path to market.

Boehringer, InterMune wow IPF field with a slate of groundbreaking trial data

The latest download of data on a pair of rival therapies for lethal cases of idiopathic pulmonary fibrosis wowed researchers in the field, producing clear evidence of their ability to slow down the lung disease and offering patients a possible set of game-changing treatments.

Boehringer's stumble is InterMune's gain in lung drug race

InterMune watched its shares jump more than 15% after Boehringer Ingelheim posted some mixed results for its rival idiopathic pulmonary fibrosis treatment, all while the biotech has nearly tripled in value over the past 30 days.

Report: InterMune eyed for a multibillion-dollar buyout

Fresh off positive results for its late-stage lung drug, InterMune has attracted some M&A interest from a flock of pharmaceutical companies, according to  Reuters, sending the biotech's shares up roughly 12% on Friday.